Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Silexion Therapeutics Ltd. (SLXN)
USD2.58
+0.08 (+3.20%)
IL NASDAQ Healthcare Biotechnology
Address
The Goldyne Savad Institute of Gene Therapy 9112001
Jerusalem, IL
Jerusalem, IL
CEO
Ilan Hadar
Website
silexion.com
IPO
2024-08-16
CIK 2022416 ISIN KYG1281K1489
Also trades on
NASDAQ Global Market · SLXN (USD)
NASDAQ Global Market · SLXNW (USD)
Description
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Moringa Acquisition Corp | MACAU | 2024-05-09 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.58
+0.08 (+3.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
636.7K
Beta
-0.33
Float Shares
561.0K
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -42.06% | -45.47% | -72.99% | -81.71% | -88.80% | -84.95% | -97.94% | -99.89% | -99.89% | -99.89% | -99.89% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
2.58
DCF (Unlevered)
3.59
+39.1%
DCF (Levered)
4.15
+61.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-26.85
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-239.4% Q1'26: +426.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +652.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-78.7% ★ Q1'26: -52.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
34.99M
34.99M – 34.99M
|
| EBITDA |
-16.48M
|
-11.62M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-16.50M
|
-11.63M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-16.44M
est: -1.06B (+98.4%)
|
-11.91M
est: -8.02M (-48.5%)
|
-5.48M
-5.48M – -5.48M
+31.7% YoY
|
-2.96M
-3.62M – -2.31M
+45.9% YoY
|
-3.55M
-3.55M – -3.55M
-19.7% YoY
|
-3.38M
-3.38M – -3.38M
+4.9% YoY
|
-518.5K
-518.5K – -518.5K
+84.6% YoY
|
| SGA |
6.73M
|
4.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.64
est: -169.35 (+98.4%)
|
-8.96
est: -6.04 (-48.5%)
|
-4.12
-4.12 – -4.12
+31.7% YoY
|
-2.23
-2.72 – -1.74
+45.9% YoY
|
-2.67
-2.67 – -2.67
-19.7% YoY
|
-2.54
-2.54 – -2.54
+4.9% YoY
|
-0.39
-0.39 – -0.39
+84.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Levin | 2.07M | 20.80% | — | 2.07M | — | 2.07M | IN | and Canada | 2024-08-22 | ↗ |
| 2 | Partners Ltd. | 2.07M | 20.80% | — | 2.07M | — | 2.07M | CO | Israel | 2024-08-22 | ↗ |
| 3 | Avner Lushi | 1.99M | 13.80% | — | 1.99M | — | 1.99M | IN | Israel | 2024-11-20 | ↗ |
| 4 | Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) | 1.99M | 13.80% | 1.99M | — | 1.99M | — | PN | China | 2024-11-20 | ↗ |
| 5 | Shlomo Noy | 1.99M | 13.80% | — | 1.99M | — | 1.99M | IN | Israel | 2024-11-20 | ↗ |
| 6 | Sponsor, LP | 1.87M | 18.80% | 1.87M | — | 1.87M | — | PN | Islands | 2024-08-22 | ↗ |
| 7 | SCHEDULE 13D - FILER IS WILDCAT AND ISSUER IS BIOMOTION | 1.02M | 10.50% | — | — | — | 1.02M | IA | — | 2024-08-22 | ↗ |
| 8 | L.P. | 200.0K | 2.00% | 200.0K | — | 200.0K | — | PN | Islands | 2024-08-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shirvan Mitchell | Officer | S-Sale | D | Ordinary Shares | 22,818 | 1.36 | 31.0K | 27,889 | D | ↗ |
| 2026-02-20 | Shirvan Mitchell | Officer | A-Award | A | Ordinary Shares | 49,726 | 0.00 | — | 50,707 | D | ↗ |
| 2026-02-20 | Peled Amnon | Director | A-Award | A | Stock Option (right to buy Ordinary Shares) | 8,904 | 1.65 | 14.7K | 8,904 | D | ↗ |
| 2026-02-20 | Noy Shlomo | Director | A-Award | A | Ordinary Shares | 9,091 | 0.00 | — | 25,399 | I | ↗ |
| 2026-02-20 | Lushi Avner | Director | A-Award | A | Ordinary Shares | 9,091 | 0.00 | — | 25,399 | I | ↗ |
| 2026-02-20 | Horenshtein Hadar Mirit | Officer | A-Award | A | Ordinary Shares | 49,726 | 0.00 | — | 50,146 | D | ↗ |
| 2026-02-20 | Hadar Ilan | Director / Officer | A-Award | A | Ordinary Shares | 64,350 | 0.00 | — | 65,471 | D | ↗ |
| 2026-02-20 | Alon Ruth | Director | A-Award | A | Stock Option (right to buy Ordinary Shares) | 10,685 | 1.65 | 17.6K | 10,685 | D | ↗ |
| 2026-02-20 | Abramov Dror Yosef | Director | A-Award | A | Stock Option (right to buy ordinary shares) | 10,685 | 1.65 | 17.6K | 10,685 | D | ↗ |
| 2025-09-15 | Levin Ilan | Director / 10% Owner | A-Award | A | Ordinary Shares | 450,000 | 4.00 | 1.80M | 456,970 | I | ↗ |
| 2025-08-07 | Levin Ilan | Director / 10% Owner | J-Other | D | Ordinary Shares | 5,550 | 0.00 | — | 6,970 | I | ↗ |
| 2025-02-09 | Peled Amnon | Director | A-Award | A | Ordinary Shares | 661 | 0.00 | — | 661 | D | ↗ |
| 2025-02-09 | Noy Shlomo | Director | A-Award | A | Stock Option (right to buy ordinary shares) | 1,872 | 18.90 | 35.4K | 1,872 | I | ↗ |
| 2025-02-09 | Lushi Avner | Director | A-Award | A | Stock Option (right to buy ordinary shares) | 1,872 | 18.90 | 35.4K | 1,872 | I | ↗ |
| 2025-02-09 | Alon Ruth | Director | A-Award | A | Stock Option (right to buy ordinary shares) | 935 | 18.90 | 17.7K | 935 | D | ↗ |
| 2025-02-09 | Abramov Dror Yosef | Director | A-Award | A | Stock Option (right to buy ordinary shares) | 935 | 18.90 | 17.7K | 935 | D | ↗ |
| 2024-12-10 | Peled Amnon | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
561.0K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-04-28 | DEFA14A | ↗ |
| 2026-04-09 | DEF 14A | ↗ |
| 2026-03-30 | PRE 14A | ↗ |
| 2026-03-16 | DEFA14A | ↗ |
| 2026-02-23 | DEF 14A | ↗ |
| 2026-02-13 | PRE 14A | ↗ |
| 2025-08-12 | DEFA14A | ↗ |
| 2025-07-31 | DEF 14A | ↗ |
| 2025-07-21 | PRE 14A | ↗ |
| 2025-07-07 | DEFA14A | ↗ |
| 2025-06-23 | DEFA14A | ↗ |
| 2025-06-16 | DEF 14A | ↗ |
| 2025-06-05 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ilan Hadar | Chairman & Chief Executive Officer | 347.8K | male |
| Mirit Horenshtein Hadar | EVice President of Finance Affairs, Chief Financial Officer & Secretary | 322.8K | female |
| Mitchell Shirvan | Chief Scientific & Development Officer | 257.8K | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLXN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
